^
Association details:
| Biomarker: | PD-L1 overexpression + KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS- mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
Published date:
02/21/2022
Excerpt:
IMpower150 was an international, open-label, randomized, phase III trial of ACP or ABCP vs BCP in 1202 patients with NSCLC enrolled....In mKRAS patients, median PFS was longer in the ABCP arm than in the ACP or BCP arms in the PD-L1-high, PD-L1-low, and PD-L1-negative subgroups (figure 3C). PFS improvements in the ABCP vs BCP arm were similar among patients with PD-L1-high (HR 0.36; 95% CI 0.17 to 0.74), PD-L1-low (HR 0.22; 95% CI 0.08 to 0.60), and PD-L1-negative (HR 0.42; 95% CI 0.20 to 0.86) expression.
Secondary therapy:
Chemotherapy
DOI:
10.1136/jitc-2021-003027
Trial ID:
